You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global and Japan Cutaneous Fibrosis Treatment Market Size, Status and Forecast 2021-2027

Cutaneous fibrosis is the accumulation of extracellular matrix (ECM) components in the dermis, leading to compromised function and altered architecture of the dermis. Development of fibrosis occurs naturally during scar formation in wound repair or is a pathological process in pro-fibrotic diseases.

Cutaneous fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-β,186. This growth factor may be derived from activated leukocytes, recruit’s macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins by dermal fibroblasts. The goal of skin fibrosis treatment is the restore abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems.

The prototype of fibrotic skin disease is scleroderma, which can be divided into whole body and local forms. Progressive systemic sclerosis (PSS) is a widespread connective tissue disease in which the fibrotic process affects not only the skin but also the lungs, heart, kidneys and gastrointestinal tract.
Europe is the largest Cutaneous Fibrosis Treatment market with about 32% market share. North America is follower, accounting for about 30% market share.
The key players are AbbVie, Bayer, Merck, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Roche, GlaxoSmithKline, Pfizer, Novartis, LEO Pharma, Actelion etc. Top 3 companies occupied about 10% market share.
Market Analysis and Insights: Global Cutaneous Fibrosis Treatment Market
The global Cutaneous Fibrosis Treatment market size is projected to reach US$ 818.9 million by 2027, from US$ 537.3 million in 2020, at a CAGR of 6.2% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cutaneous Fibrosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cutaneous Fibrosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cutaneous Fibrosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cutaneous Fibrosis Treatment market.
Cutaneous Fibrosis Treatment Breakdown Data by Type
Anti-Fibrotic Drugs
In 2018, Immunotherapy accounted for a major share of 49% the global Cutaneous Fibrosis Treatment market. And this product segment is poised to reach 340 million US$ by 2025 from 232.5 million US$ in 2018.
Cutaneous Fibrosis Treatment Breakdown Data by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
In Cutaneous Fibrosis Treatment market, the Hospitals Pharmacies holds an important share in terms of application, and it is expected to reach a revenue of 385.25 by 2025, at a CAGR of 5.71% during 2019 and 2025.
Based on regional and country-level analysis, the Cutaneous Fibrosis Treatment market has been segmented as follows:
North America
United States
Rest of Europe
South Korea
Southeast Asia
Rest of Asia-Pacific
Latin America
Middle East & Africa
Saudi Arabia
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Cutaneous Fibrosis Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.

The following players are covered in this report:
Bristol-Myers Squibb
Boehringer Ingelheim
LEO Pharma

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cutaneous Fibrosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunotherapy
1.2.3 Corticosteroids
1.2.4 Anti-Fibrotic Drugs
1.2.5 Immunoglobulins
1.3 Market by Application
1.3.1 Global Cutaneous Fibrosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cutaneous Fibrosis Treatment Market Perspective (2016-2027)
2.2 Cutaneous Fibrosis Treatment Growth Trends by Regions
2.2.1 Cutaneous Fibrosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cutaneous Fibrosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Cutaneous Fibrosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Cutaneous Fibrosis Treatment Industry Dynamic
2.3.1 Cutaneous Fibrosis Treatment Market Trends
2.3.2 Cutaneous Fibrosis Treatment Market Drivers
2.3.3 Cutaneous Fibrosis Treatment Market Challenges
2.3.4 Cutaneous Fibrosis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cutaneous Fibrosis Treatment Players by Revenue
3.1.1 Global Top Cutaneous Fibrosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Cutaneous Fibrosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Cutaneous Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cutaneous Fibrosis Treatment Revenue
3.4 Global Cutaneous Fibrosis Treatment Market Concentration Ratio
3.4.1 Global Cutaneous Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cutaneous Fibrosis Treatment Revenue in 2020
3.5 Cutaneous Fibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Cutaneous Fibrosis Treatment Product Solution and Service
3.7 Date of Enter into Cutaneous Fibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cutaneous Fibrosis Treatment Breakdown Data by Type
4.1 Global Cutaneous Fibrosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Cutaneous Fibrosis Treatment Forecasted Market Size by Type (2022-2027)

5 Cutaneous Fibrosis Treatment Breakdown Data by Application
5.1 Global Cutaneous Fibrosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Cutaneous Fibrosis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cutaneous Fibrosis Treatment Market Size (2016-2027)
6.2 North America Cutaneous Fibrosis Treatment Market Size by Type
6.2.1 North America Cutaneous Fibrosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Cutaneous Fibrosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Cutaneous Fibrosis Treatment Market Size by Type (2016-2027)
6.3 North America Cutaneous Fibrosis Treatment Market Size by Application
6.3.1 North America Cutaneous Fibrosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Cutaneous Fibrosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Cutaneous Fibrosis Treatment Market Size by Application (2016-2027)
6.4 North America Cutaneous Fibrosis Treatment Market Size by Country
6.4.1 North America Cutaneous Fibrosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Cutaneous Fibrosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Cutaneous Fibrosis Treatment Market Size (2016-2027)
7.2 Europe Cutaneous Fibrosis Treatment Market Size by Type
7.2.1 Europe Cutaneous Fibrosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Cutaneous Fibrosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Cutaneous Fibrosis Treatment Market Size by Type (2016-2027)
7.3 Europe Cutaneous Fibrosis Treatment Market Size by Application
7.3.1 Europe Cutaneous Fibrosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Cutaneous Fibrosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Cutaneous Fibrosis Treatment Market Size by Application (2016-2027)
7.4 Europe Cutaneous Fibrosis Treatment Market Size by Country
7.4.1 Europe Cutaneous Fibrosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Cutaneous Fibrosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cutaneous Fibrosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Type
8.2.1 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Application
8.3.1 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Region
8.4.1 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cutaneous Fibrosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cutaneous Fibrosis Treatment Market Size (2016-2027)
9.2 Latin America Cutaneous Fibrosis Treatment Market Size by Type
9.2.1 Latin America Cutaneous Fibrosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Cutaneous Fibrosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Cutaneous Fibrosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Cutaneous Fibrosis Treatment Market Size by Application
9.3.1 Latin America Cutaneous Fibrosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Cutaneous Fibrosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Cutaneous Fibrosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Cutaneous Fibrosis Treatment Market Size by Country
9.4.1 Latin America Cutaneous Fibrosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Cutaneous Fibrosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cutaneous Fibrosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Type
10.2.1 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Application
10.3.1 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Country
10.4.1 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cutaneous Fibrosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Cutaneous Fibrosis Treatment Introduction
11.1.4 AbbVie Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Cutaneous Fibrosis Treatment Introduction
11.2.4 Bayer Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.2.5 Bayer Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Cutaneous Fibrosis Treatment Introduction
11.3.4 Merck Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Cutaneous Fibrosis Treatment Introduction
11.4.4 Bristol-Myers Squibb Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Cutaneous Fibrosis Treatment Introduction
11.5.4 Sanofi Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Cutaneous Fibrosis Treatment Introduction
11.6.4 Boehringer Ingelheim Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Cutaneous Fibrosis Treatment Introduction
11.7.4 Roche Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.7.5 Roche Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Cutaneous Fibrosis Treatment Introduction
11.8.4 GlaxoSmithKline Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.8.5 GlaxoSmithKline Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Cutaneous Fibrosis Treatment Introduction
11.9.4 Pfizer Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Cutaneous Fibrosis Treatment Introduction
11.10.4 Novartis Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.10.5 Novartis Recent Development
11.11 LEO Pharma
11.11.1 LEO Pharma Company Details
11.11.2 LEO Pharma Business Overview
11.11.3 LEO Pharma Cutaneous Fibrosis Treatment Introduction
11.11.4 LEO Pharma Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.11.5 LEO Pharma Recent Development
11.12 Actelion
11.12.1 Actelion Company Details
11.12.2 Actelion Business Overview
11.12.3 Actelion Cutaneous Fibrosis Treatment Introduction
11.12.4 Actelion Revenue in Cutaneous Fibrosis Treatment Business (2016-2021)
11.12.5 Actelion Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140